Literature DB >> 24756833

A case report--treatment of metastatic colorectal cancer in a patient on hemodialysis.

Ryan M Bolonesi1, Jane E Rogers, Imad Shureiqi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24756833     DOI： 10.1007/s12029-014-9611-1

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  12 in total

1.  Pharmacokinetics of bevacizumab in haemodialysis.

Authors:  Nathalie Garnier-Viougeat; Olivier Rixe; Gilles Paintaud; David Ternant; Danielle Degenne; Roger Mouawad; Gilbert Deray; Hassane Izzedine
Journal:  Nephrol Dial Transplant       Date:  2006-11-08       Impact factor: 5.992

2.  Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy.

Authors:  Takahiro Horimatsu; Shin'ichi Miyamoto; Shuko Morita; Yoko Mashimo; Yasumasa Ezoe; Manabu Muto; Tsutomu Chiba
Journal:  Cancer Chemother Pharmacol       Date:  2011-04-16       Impact factor: 3.333

Review 3.  Commentary: Oncologic drugs in patients with organ dysfunction: a summary.

Authors:  Diana Superfin; Andrea A Iannucci; Angela M Davies
Journal:  Oncologist       Date:  2007-09

4.  Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure.

Authors:  R Inauen; R Cathomas; T Boehm; D Koeberle; B C Pestalozzi; S Gillessen; R von Moos
Journal:  Oncology       Date:  2007-12-21       Impact factor: 2.935

5.  Delayed elimination of SN-38 in cancer patients with severe renal failure.

Authors:  Ken-ichi Fujita; Yu Sunakawa; Keisuke Miwa; Yuko Akiyama; Minako Sugiyama; Kaori Kawara; Hiroo Ishida; Keishi Yamashita; Keiko Mizuno; Shigehira Saji; Wataru Ichikawa; Wataru Yamamoto; Fumio Nagashima; Toshimichi Miya; Masaru Narabayashi; Yuichi Ando; Takashi Hirose; Yasutsuna Sasaki
Journal:  Drug Metab Dispos       Date:  2010-10-27       Impact factor: 3.922

6.  Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis.

Authors:  Yoshihisa Watayo; Hidekazu Kuramochi; Kazuhiko Hayashi; Go Nakajima; Hirotaka Kamikozuru; Masakazu Yamamoto
Journal:  Jpn J Clin Oncol       Date:  2010-01-18       Impact factor: 3.019

7.  Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.

Authors:  Laurence Vénat-Bouvet; Franck Saint-Marcoux; Christian Lagarde; Pierre Peyronnet; Valérie Lebrun-Ly; Nicole Tubiana-Mathieu
Journal:  Anticancer Drugs       Date:  2007-09       Impact factor: 2.248

Review 8.  Elimination mechanisms of therapeutic monoclonal antibodies.

Authors:  Mohammad A Tabrizi; Chih-Ming L Tseng; Lorin K Roskos
Journal:  Drug Discov Today       Date:  2006-01       Impact factor: 7.851

9.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

10.  Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study.

Authors:  Fatma M Shebl; Joan L Warren; Paul W Eggers; Eric A Engels
Journal:  BMC Nephrol       Date:  2012-07-26       Impact factor: 2.388
View more
  1 in total

Review 1.  Patient considerations in metastatic colorectal cancer - role of panitumumab.

Authors:  Jane E Rogers
Journal:  Onco Targets Ther       Date:  2017-04-07       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.